PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (26th April 2018) - Loibl, S; Majewski, I; Guarneri, V; Nekljudova, V; Holmes, E; Bria, E; Denkert, C; Schem, C; Sotiriou, C; Loi, S; Untch, M; Conte, P; et al.